Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.

NCT00381303 is registered in ClinicalTrials.gov with Tibotec, Inc as lead sponsor.

NCT NCT00381303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00381303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.
Lead sponsor
Tibotec, Inc
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
December 31, 2008
Enrollment
429 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, infectious